Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

No longer available × INDUSTRY × ficlatuzumab × Clear all

Status

Completed 3 Terminated 1 Recruiting 1 No longer available 1

Sponsor Class

Study Type

Expanded_access 1

Sponsor

Conditions

Mullerian Mixed Tumor of Ovary 1

Interventions

dabrafenib 4 trametinib 3 nilotinib 3 midostaurin 3 elotuzumab 3 Nivolumab 3 talimogene laherparepvec 2 regorafenib 2 Suspensions 2 Prednisone 2 Powders 2 Panobinostat 2 Melphalan 2 Lenalidomide 2 Ipilimumab 2 Everolimus 2 Dexamethasone 2 Bortezomib 2 zanubrutinib 1 zanidatamab 1 venetoclax 1 veliparib 1 tucatinib 1 tazemetostat 1 taletrectinib 1 surufatinib 1 sugemalimab 1 selitrectinib 1 ruxolitinib 1 rovalpituzumab tesirine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02090127 2015-07-29

Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient

AVEO Pharmaceuticals, Inc.

No longer available

Mullerian Mixed Tumor of Ovary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡